Supplementary Figure 21. Subgroup analysis of Mortality for COVID-19 with Incidence in Control from 40% to 80%

Subgroup	Glucocorticoids (No. events/total)	Control (No. events/total)	RR	95% CI	Weight %	Incidence of events in control	Design type of included studies	Risk of bias of included studies
Age								
Elder(I^2=0%, p=.39)	241/594	467/1051	0.87	[0.73; 1.04]	NA	0.44	RCTs	Non−high
Elder(I^2=0%, p=.98)	98/438	30/74	0.55	[0.50; 0.61]	NA	0.41	Observational	Low/Some concerns/High
ARDS								
With ARDS(I^2=NA%, p=NA)	13/24	13/23	0.96	[0.57; 1.61]	NA	0.57	RCTs	Non−high
With ARDS(I^2=95%, p<.001)	160/536	117/211	0.51	[0.35; 0.74]	NA	0.55	Observational	Low/Some concerns/High
With ARDS(I^2=0%, p=.51)	61/196	54/98	0.39	[0.22; 0.69]	NA	0.55	Observational	Low
Diabetes								
With diabetes(I^2=NA%, p=NA)	35/39	4/9	2.02	[1.53; 2.67]	NA	0.44	Observational	High
Doses of glucocorticoids								
Low dose(I^2=NA%, p=NA)	13/24	13/23	0.96	[0.57; 1.61]	37	0.57	RCTs	Non−high
Low dose(I^2=98%, p<.001)	142/323	73/142	0.48	[0.23; 1.00]	54.6	0.51	Observational	Low/Some concerns/High
Medium−high dose(I^2=NA%, p=NA)	85/151	91/148	0.92	[0.76; 1.11]	40.4	0.61	RCTs	Non−high
Medium−high dose(I^2=3%, p=.38)	79/446	48/120	0.41	[0.30; 0.56]	45.4	0.4	Observational	Low/Some concerns/High
Medium−high dose(I^2=NA%, p=NA)	27/156	12/30	0.26	[0.13; 0.53]	NA	0.4	Observational	Low
Pulse(I^2=NA%, p=NA)	2/34	12/28	0.14	[0.03; 0.60]	22.6	0.43	RCTs	Non−high
Severity of illness								
Severe(I^2=85%, p=.009)	87/185	103/176	0.41	[0.06; 2.67]	44	0.59	RCTs	Non−high
Severe(I^2=97%, p<.001)	67/171	26/46	0.65	[0.22; 1.91]	25.4	0.57	Observational	Low/Some concerns/High
Critically severe(I^2=15%, p=.28)	108/348	296/706	0.75	[0.59; 0.95]	56	0.42	RCTs	Non−high
Critically severe(I^2=98%, p<.001)	438/1003	243/398	0.71	[0.54; 0.94]	68.6	0.61	Observational	Low/Some concerns/High
Critically severe(I^2=0%, p=.51)	61/196	54/98	0.39	[0.22; 0.69]	NA	0.55	Observational	Low
Severe or critically severe(I^2=70%, p=.02)	195/533	399/882	0.79	[0.63; 0.99]	NA	0.45	RCTs	Non−high
Severe or critically severe(I^2=97%, p<.001)	517/1244	271/448	0.66	[0.47; 0.92]	NA	0.6	Observational	Low/Some concerns/High
Types of glucocorticoids								
Dexamethasone(I^2=NA%, p=.01)	85/151	91/148	0.92	[0.76; 1.11]	40.4	0.61	RCTs	Non−high
Methylprednisolone(I^2=84%, p=NA)	15/58	25/51	0.41	[0.06; 2.75]	59.6	0.49	RCTs	Non−high
Methylprednisolone(I^2=97%, p<.001)	267/869	163/330	0.47	[0.33; 0.66]	NA	0.49	Observational	Low/Some concerns/High
Methylprednisolone(I^2=NA%, p=NA)	27/156	12/30	0.26	[0.13; 0.53]	NA	0.4	Observational	Low